Peptide BPC-157 exhibits both preventive and mitigating nephroprotective effects
Current evidence suggests that GLP-1 medications, when used with appropriate patient selection and monitoring, likely do not pose significant long-term threats to vision for most patients and may contribute to better overall ocular outcomes through improved metabolic control
In this article, well break down 5 key differences between Ozempic and other GLP-1 receptor agonists, helping you make an informed decision
Huberman also discusses how habits can be categorized as either immediate goal-based or identity-based, and introduces the concept of linchpin habitsfoundational behaviors that can naturally lead to the development of other positive habits
The Selenium-Glutathione-Thyroid Axis: A Critical Connection Understanding the glutathione-thyroid relationship requires understanding its inseparable connection to selenium - one of the most important micronutrients for thyroid health
Development, preclinical, and early clinical data on the GIP/GLP-1 receptor agonist tirzepatide Among the GIP/GLP-1 receptor agonists, tirzepatide (LY3298176) is the compound that is the most advanced in development and the first substance in this class that has received approval for the therapy of T2D by the FDA in May 2022 (manufacturer Eli Lilly Comp., trade name Mounjaro ) (5355)
